Dermatology

Caregivers need to help patients with psoriasis understand the importance of lifestyle behavior choices.

The role of vitamin D in diseases such as psoriatic arthritis, systemic lupus erythematosus, and rheumatoid arthritis.

Discovery holds promise for patients with Crohn's disease, diabetes, ulcerative colitis, and more.

Psoriasis treatment may improve more than just skin issues.

A 10-second assessment may be as effective as more complex tests.

Elevated risk found for heart arrhythmia, specifically atrial fibrillation.

Lithium chloride found to slow degradation.

Patients who received secukinumab sustained improvements over one year of treatment.

Drug decreases enthesitis and dactylitis by blocking the production of cytokines that promote inflammation.

Study finds improved screening needed for condition.

Physical aspects and quality of life issues improve with treatment.

Treatment blocks signals that may lead to inflammation.

Psoriasis treatment among drugs seized by authorities.

Experimental treatment blocks signaling protein.

Genetic variants found that are associated with psoriatic arthritis, but not psoriasis.

Patients with celiac disease are known to be deficient in the amino acid L-carnitine, a nutrient essential for muscle energy production.

Treatment with secukinumab led to clearer skin after 12 weeks compared with placebo.

The FDA today approved Novartis' secukinumab (Cosentyx), an interleukin-17A antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

In a head-to-head phase 3b study, Novartis' secukinumab (Cosentyx) beat Janssen Pharmaceuticals' ustekinumab (Stelara) in clearing the skin of patients with psoriasis.

Patients with autoimmune conditions have an increased risk of developing shingles due to immune-suppressing treatment regimens.

More severe psoriasis associated with clinically significant cardiovascular risk.

Two doses of brodalumab generated better results in moderate-to-severe plaque psoriasis compared with ustekinumab (Stelara).